Free Trial

Achieve Life Sciences Q3 2024 Earnings Report

Achieve Life Sciences logo
$3.09 +0.02 (+0.65%)
As of 01/17/2025 04:00 PM Eastern

Achieve Life Sciences EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.26
Beat/Miss
Missed by -$0.10
One Year Ago EPS
-$0.34

Achieve Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achieve Life Sciences Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Conference Call Resources

Achieve Life Sciences Earnings Headlines

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest Update
Achieve Life Sciences appoints Slaoui, Phelan to board of directors
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
Oppenheimer Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)
See More Achieve Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email.

About Achieve Life Sciences

Achieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

View Achieve Life Sciences Profile

More Earnings Resources from MarketBeat